BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-04-10 17:30 |
NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)
|
English | 212.3 KB | ||
| 2019-03-22 00:40 |
BioArctics partner Eisai initierar den bekräftande Fas 3-studien av BAN2401 för…
|
Swedish | 195.1 KB | ||
| 2019-03-22 00:40 |
BioArctic’s partner Eisai initiates the confirmatory Phase 3 study of BAN2401 i…
|
English | 195.8 KB | ||
| 2019-03-21 18:35 |
BioArctic – Statement regarding today’s trading halt
|
English | 192.8 KB | ||
| 2019-03-21 18:35 |
BioArctic - Kommentar med anledning av handelsstopp
|
Swedish | 190.0 KB | ||
| 2019-03-13 22:30 |
BioArctic meddelar start av klinisk Fas 1-studie med ABBV-0805 för Parkinsons s…
|
Swedish | 183.6 KB | ||
| 2019-03-13 22:30 |
BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease
|
English | 186.1 KB | ||
| 2019-03-07 08:45 |
BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study …
|
English | 200.7 KB | ||
| 2019-03-07 08:45 |
BioArctic: Eisai informerar om tidplanen för den enda bekräftande Fas 3-studien…
|
Swedish | 198.2 KB | ||
| 2019-02-14 08:00 | Swedish | 624.0 KB | |||
| 2019-02-14 08:00 | English | 679.7 KB | |||
| 2019-02-13 08:00 |
BioArctics produktkandidat SC0806 för behandling av patienter med komplett rygg…
|
Swedish | 191.3 KB | ||
| 2019-02-13 08:00 |
BioArctic’s product candidate SC0806 for treatment of patients with complete sp…
|
English | 191.4 KB | ||
| 2019-02-11 17:00 |
BioArctic: Amerikanska läkemedelsmyndigheten, FDA, godkänner Investigational Ne…
|
Swedish | 210.9 KB | ||
| 2019-02-11 17:00 |
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug …
|
English | 210.6 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
